摘要
目的探讨非小细胞肺癌（NSCLC）患者治疗前后血浆中肿瘤型M2丙酮酸激酶（TuM2-PK）的表达水平及其与肿瘤的近期疗效及预后的关系。方法用ELISA法分别检测83例NSCLC患者（其中31例NSCLC患者手术治疗，52例患者失去外科手术机会而行内科治疗）和106例健康对照者血浆中的TuM2-PK表达水平，并进行24个月的随访。结果NSCLC手术后血浆TuM2-PK浓度（13．5U／ml）与术前（25．4U／ml）相比，差异有统计学意义（P〈0．05）。经内科治疗后，缓解组血浆TuM2-PK浓度（11．5U／ml）与治疗前（22．6U／ml）相比显著下降（P〈0．05）；进展组血浆TuM2-PK浓度（60．8U／ml）与治疗前（23．7U／ml）相比显著升高（P〈0．05）；稳定组血浆TuM2-PK浓度治疗前后差异无统计学意义（P〉0．05）。手术后TuM2-PK阳性率显著下降，而化疗后阳性率下降不明显。在随访期间，手术后TuM2-PK阳性患者肿瘤复发或转移率（67％，6／9）高于术后阴性患者（5％，1／20）。结论检测NSCLC患者血中肿瘤标志物TuM2-PK表达水平对预测肿瘤微转移有一定的临床意义，有助于疗效的评估以及预后的预测。
Objective To study the expression of tumor type M2 pyruvate kinase（ tumor M2-PK） in non- small cell lung cancer （NSCLC） and their correlation with treatment response and prognosis. Methods The concentration of tumor M2-PK in plasma was detected by ELISA in 106 healthy controls and 83 NSCLC patients. The patients were followed for 24 months. Results The patients after surgical operation showed marked reduction in plasma tumor M2-PK level（ 13.5 U/ml vs 25.4 U/ml ,P 〈 0.05 ）. In the 15 patients with tumor remission the tumor M2-PK level（ 11.5 U/ml） was significantly lower than that （ 22.6 U/ml） before treatment （ P 〈 0.05 ）. In the 20 patients with progressive disease the tumor M2-PK level（60.8 U/ml） was significantly higher than that（23.7 U/ml） of pre- treatment （P 〈 0.05 ）. The tumor ME-PK concentration did not differ signigicantly before and after treatment in 17 patients with stable disease. The positive rates of tumor ME-PK decreased significantly after operation ,but there was no significant change after chemotherapy. In the follow-up, the rate of relapse and metastasis was higher in patients （67% ,6/9） with a positive tumor M2-PK postoperatively than those with a negative tumor M2-PK（5%, 1/20）. Conclusions Plasma tumor M2-PK might be a useful marker in the detection of tumor micrometastases in NSCLC , and in evaluating treatment response and prognosis.
出处
《中国综合临床》
2009年第8期830-832,共3页
Clinical Medicine of China
关键词
非小细胞肺癌
丙酮酸激酶
肿瘤标志
Non-small cell lung cancer
Pyruvate kinase
Tumor marker
